WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific (NYSE: TMO), the world leader in serving science, today announced that it has received approval from the European Commission (EC) for its pending acquisition of Life Technologies Corporation (NASDAQ: LIFE).
To expedite the approval, Thermo Fisher has committed to divest of its cell culture (sera and media), gene modulation and magnetic beads businesses. Combined, these businesses had 2012 revenue of approximately $225 million.
The acquisition remains subject to additional regulatory approvals, including the U.S. Federal Trade Commission (FTC). Based on its discussions with the FTC, Thermo Fisher does not believe any additional divestures will be required in order to receive U.S. approval. The company is working with the regulatory agencies to complete the transaction as soon as possible, and still expects to close in early 2014.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenue of $13 billion, we have 39,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through three premier brands, Thermo Scientific, Fisher Scientific and Unity Lab Services, which offer a unique combination of innovative technologies, convenient purchasing options and a single solution for laboratory operations management. Our products and services help our customers solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Visit www.thermofisher.com.
Media Contact Information:
Thermo Fisher Scientific
Karen Kirkwood, 781-622-1306
[email protected]
www.thermofisher.com
Investor Contact Information:
Ken Apicerno, 781-622-1294
[email protected]